BACKGROUND Botulinum neurotoxin type A (BoNT-A) reduces upper-extremity poststroke spasticity when given 6 or more months after stroke. Effects on functional use of the arm and hand are less apparent. OBJECTIVE To determine the effect and safety of very early use of BoNT-A for patients with upper-limb spasticity. METHODS The Asia Botulinum Toxin-A Clinical Trial DESIGN ed for Early Post-s...

A recent study claimed that botulinum toxin A (BTX-A) injection into the calf muscle of cerebral palsy (CP) children did not change the intrinsic stiffness. Contrary to this recent report, in our case, decreased muscle spasticity, which was measured using a modified Ashworth scale, and increased Gross Motor Function Measure score were demonstrated at 4 weeks after intensive rehabilitation treat...

OBJECTIVE To compare the Tardieu Scale as a clinical measure of spasticity after stroke with the Ashworth Scale. DESIGN Cross-sectional study. PARTICIPANTS Sixteen people, living in the community three years after their stroke. MAIN MEASURES The Ashworth Scale and Tardieu Scale as well as laboratory measures of spasticity (stretch-induced electromyographic (EMG) activity) and contracture ...

The aim of this observational study was to assess the efficacy of a tetrahydrocannabinol-cannabidiol (THC : CBD) oromucosal spray on spasticity using the stretch reflex in patients with multiple sclerosis (MS). Numeric rating scale (NRS) for spasticity, modified Ashworth scale (MAS), and the stretch reflex were assessed before and during treatment in 57 MS patients with spasticity eligible for ...